Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SUPERNUS PHARMACEUTICALS, INC. | a12-14277_1ex99d1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2012
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware | ||
|
(State or other jurisdiction of Incorporation) | ||
|
|
|
|
|
0-50440 |
|
20-2590184 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On June 7, 2012 Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release describing the Company’s financial results for the quarter ended March 31, 2012. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following document is furnished as an Exhibit pursuant to Item 2.02 hereof:
Exhibit 99.1 — Press Release dated June 7, 2012 of the Company regarding financial performance for the quarter ended March 31, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized
|
|
SUPERNUS PHARMACEUTICALS, INC. | ||
|
|
|
| |
|
DATED: June 7, 2012 |
By: |
/s/ |
Jack A. Khattar |
|
|
|
|
Jack A. Khattar |
|
|
|
|
President and Chief Executive Officer |